Minerva Neurosciences (NERV) Plunges Far Below Analyst Target Price

Small-cap Healthcare company Minerva Neurosciences has logged a -40.2% change today on a trading volume of 413,152. The average volume for the stock is 311,085.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Based in Waltham, United States the company has 9 full time employees and a market cap of $7,476,266.

The company is now trading -76.67% away from its average analyst target price of $6 per share. The 3 analysts following the stock have set target prices ranging from $3 to $8, and on average give Minerva Neurosciences a rating of buy.

Over the last year, NERV shares have gone down by -65.4%, which represents a difference of -45.3% when compared to the S&P 500. The stock's 52 week high is $15.27 per share and its 52 week low is $1.4.


The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.